Results 131 to 140 of about 137,029 (384)

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. [PDF]

, 2019
BACKGROUND AND AIMS:Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach.
Cao, Charlie, Dulai, Parambir S, Lasch, Karen, Osterman, Mark T, Riaz, Faisal, Sandborn, William J   +5 more
core  

Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (focus) initiative [PDF]

, 2018
Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics.
Acharya, Nisha, Adan, Alfredo, Agrawal, Rupesh, Akkoc, Nurullah, Al Ghamdi, Saed, Al Ghamdi, Turki, Al Saati, Anood, Al-Dhibi, Hassan A., Al-Shamarani, Mohamed, Alsabaani, Nasser, Bachta, Artur, Barisani-Asenbauer, Talin, Beare, Nicholas, Belga Ottoni Porto, Fernanda, Blanco, Ricardo, Brézin, Antoine P., Carreño, Ester, Chan Sook Yee, Anita, Chandran, Vinod, Chiquet, Christophe, Cimbalas, Andrius, Cimino, Luca, Cordero-Coma, Miguel, Correspondence information about the author FMedSci, FRCOphth, Cristobal, Couto, Cuevas, Miguel, Davis, Janet L., de Boer, Joke, de la Torre, Alejandra, De Schryver, Ilse, Derzko-Dzulynsky, Larissa, Diaz-Valle, David, Dick, Andrew D., Dick, FRCOphth Andrew D., Dick†, FRCOphth Andrew D., Eugenia Duran Merino, Claudia, Eurico da Fonseca, João, Facsko, Andrea, Figueira, Luis, FMedSci,, Fonollosa, Alejandro, Fortin, Eric, FRCOphth,, FRCPCH, FRCP, FRCS, FRCOphth, FRCSEd(Ophth), FRCOphth, Gale, Richard, Galeazzi, Mauro, Garcia, Sandra, Gašperšič, Nataša, Goldstein, Debra, Guedes, Marta, Guex-Crosier, Yan, Gul, Ahmet, Hamam, Rola, Haroon, Muhammad, Hasegawa, Kenichi, Hee Chng, Hiok, Heiligenhaus, Arnd, Hisae Yamamoto, Joyce, Hooper, Claire, Hwang, De-Kuang, Hwang, Yih-Shiou, Jr., Rubens Belfort, Juanola, Xavier, Kaburaki, Toshikatsu, Kadayifcilar, Sibel, Kempen, John, Kezuka, Takeshi, Kherani, Amin, Kiak Lim, Wee, Kirsimäe, Maarja, Kotaniemi, Kaisu, Kraut, Aleksandra, Kubicka-Trząska, Agnieszka, Kuffova, Lucia, Lightman, Susan, Lim, Lyndell, MA, MD, Maria Garcia Ruiz de Morales, Jose, Massimo Accorinti, MBChB(Hons), McCluskey, Peter, McGuire, Mairide, MD,, MD,, MD,, MD,, MD†,, Mirabelli, Pierfrancesco, Miserocchi, Elisabetta, Misiuk-Hojło, Marta, Muccioli, Cristina, Murphy, Conor, Murray, Philip I., Muñoz, Santiago, Nagy, Zoltan, Namba, Kenichi, Nascimento, Heloisa, Neri, Piergiorgio, Nguyen, Quan, O'Gradaigh, Donncha, Omair, Mohammed, Otsa, Kati, Ozyazgan, Yilmaz, Pablo, Franco, PAROLI, Maria Pia, Phaik Chee, Soon, PhD, MD, PhD, MD, PhD, MD, PhD, MD, Pleyer, Uwe, Poór, Gyula, Proença, Rui, Rabinovitch, Theodore, Ramanan, Athimalaipet V., Read, Russell, Rebrov, Margarita, Recillas-Gispert, Claudia, Rosenbaum, James T., Rothova, Aniki, Salah, Sawsen, Salek, Sherveen, Schwartzman, Sergio, Seve, Pascal, Sharma, Srilakshmi, Siak, Jay, Sims, Joanne, Sohár, Nicolette, Sonoda, Koh-Hei, Steeples, Laura, Suhler, Eric, Szepessy, Zsuzsanna, Szántó, Sándor, Tappeiner, Christoph, the author FMedSci, Email, Thorne, Jennifer, Tugal Tutkun, Ilknur, Turno-Kręcicka, Anna, Van Calster, Joachim, van der Horst-Bruinsma, Irene, Vidovič Valentinčič, Nataša, Vitale, Albert, Voorduin Ramos, Stephanie, Vukojevic, Nenad, Wakefield, Denis, Willermain, François, Yalcindag, Nilufer, Yeh, Stephen, Zemaitiene, Reda, Ziouzina, Olga   +150 more
core   +1 more source

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

Journal of Crohn's & Colitis, 2016
BACKGROUND AND AIMS Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory bowel diseases are lacking.
K. Gecse, B. Lovász, K. Farkas, J. Banai, L. Bene, B. Gasztonyi, P. Golovics, T. Kristof, L. Lakatos, Á. Csontos, M. Juhász, F. Nagy, K. Palatka, M. Papp, Á. Patai, L. Lakner, Á. Salamon, T. Szamosi, Z. Szepes, G. Tóth, Á. Vincze, B. Szalay, T. Molnár, P. Lakatos   +23 more
semanticscholar   +1 more source

The Inflation Reduction Act and Etanercept

Arthritis &Rheumatology, EarlyView.
Charles L. Bennett, Jason B. Gibbons, Chadi Nabhan, Kenneth R. Carson, June M. McKoy, Kevin B. Knopf, Gerald Anderson   +6 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately‐to‐Severely Active Crohn's Disease

The Journal of Clinical Pharmacology, EarlyView.
Abstract This study aimed to characterize the pharmacokinetics (PK) of etrolizumab, an IgG1‐humanized monoclonal anti‐β7 integrin antibody, and assess its exposure–response (ER) relationship for key clinical outcomes in patients with moderately‐to‐severely active Crohn's disease.
Anita Moein, Jakob Ribbing, Moustafa M. A. Ibrahim, Wenhui Zhang, Nastya Kassir   +4 more
wiley   +1 more source

Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study

Gut and Liver, 2015
Background/AimsIn patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission.
doaj   +1 more source

Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel

Respiratory Medicine Case Reports, 2016
Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction.
Ying Zhou, Elyse E. Lower, Huiping Li, Robert P. Baughman   +3 more
doaj   +1 more source

Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies [PDF]

, 2015
The idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group of chronic disorders that include dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM).
De Paepe, Boel, Zschüntzsch, Jana
core   +3 more sources

Intestinal involvement in graft versus host disease in children: An overview by the ESPGHAN Gastroenterology Committee

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Graft versus host disease (GVHD) is a complication that frequently occurs after haematopoietic stem cell transplantation and concerns many children in paediatric haematology‐oncology and bone marrow transplantation departments. It can affect various organs, with the skin, gastrointestinal tract and liver being the most commonly involved.
Marina Vincent, Amit Assa, Osvaldo Borrelli, Matjaž Homan, Javier Martin‐de‐Carpi, Zrinjka Misak, Maria Giovanna Puoti, Isabelle Scheers, Sara Sila, Caterina Strisciuglio, Christos Tzivinikos, Jernej Dolinsek, Emmanuel Mas   +12 more
wiley   +1 more source

TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents [PDF]

, 2017
BACKGROUND: Lymphocyte expansion and true lymphocytosis are commonly observed in the everyday clinical practice. The meaning of such phenomenon is often poorly understood so that discrimination between benign and malignant lymphocytosis remains ...
Amodeo, Rachele, Bove, Maurizio, Cox, Maria Christina, D'Amelio, Raffaele, DI ROSA, Roberta, Lagana', Bruno, Markovic, Milica, PICCHIANTI DIAMANTI, Andrea, Pilozzi, Emanuela, Rosado, Maria Manuela, Salemi, Simonetta, Sorgi, Maria Laura   +11 more
core   +1 more source